Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis

Overview

Journal Dermatology

Publisher Karger

Specialty Dermatology

Date 2021 Nov 25

PMID 34823247

Citations 5

Authors

Georgios Kokolakis

Kasper Vadstrup

Jes B Hansen

Jose Manuel Carrascosa

Affiliations

Soon will be listed here.

Abstract

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial for limiting PsA progression and preventing disability.

Objectives: The aim of this study was to compare the efficacy of brodalumab versus ustekin-umab and the impact on QoL in patients with moderate-to-severe plaque psoriasis, by concomitant PsA status.

Methods: This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials evaluated complete skin clearance (100% improvement of Psoriasis Area and Severity Index [PASI 100]), improvement in symptom severity (Psoriasis Symptom Inventory [PSI] response), and QoL (Dermatology Life Quality Index [DLQI] score of 0/1) by concomitant PsA status. A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI 100 or inadequate response.

Results: This analysis included 929 patients with moderate-to-severe psoriasis. Concomitant PsA was present in 79/339 (23%) and 110/590 (19%) patients receiving brodalumab 210 mg and ustekinumab, respectively. At Week 52, odds ratios (ORs) (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekin-umab were 3.15 (1.52-6.55, p = 0.0015) in patients with concomitant PsA and 3.05 (2.19-4.26, p < 0.0001) in patients without concomitant PsA. Corresponding Week 52 ORs (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 2.05 (1.07-3.90, p = 0.0277) and 1.83 (1.32-2.53, p = 0.0002); Week 52 ORs (95% CIs) for PSI ≤8 with brodalumab versus ustekinumab were 3.42 (1.43-8.18, p = 0.0036) and 1.40 (1.01-1.95, p = 0.0434). The 52-week cumulative incidence of patients achieving PASI 100 was significantly higher for brodalumab versus ustekinumab in patients with concomitant PsA (p = 0.0001) and in those without concomitant PsA (p < 0.0001).

Conclusions: Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status.

Citing Articles

An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.

Soni B, Shivgotra R, Trehan K, Chhina A, Saini M, Jain S Curr Drug Targets. 2024; 25(5):353-373.

PMID: 38500274 DOI: 10.2174/0113894501292755240304063020.

Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.

Puig L, Costanzo A, de Jong E, Torres T, Warren R, Wapenaar R Am J Clin Dermatol. 2023; 25(2):315-325.

PMID: 37804472 PMC: 10866772. DOI: 10.1007/s40257-023-00816-1.

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry.

Hugo J, Kojanova M, Turkova B, Gkalpakiotis S Dermatol Ther (Heidelb). 2023; 13(3):787-801.

PMID: 36723775 PMC: 9890420. DOI: 10.1007/s13555-023-00893-4.

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.

Kokolakis G, Ghoreschi K J Clin Med. 2023; 12(1).

PMID: 36614836 PMC: 9820893. DOI: 10.3390/jcm12010035.

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.

Jiang Y, Chen Y, Yu Q, Shi Y BioDrugs. 2023; 37(1):35-55.

PMID: 36592323 PMC: 9837020. DOI: 10.1007/s40259-022-00569-z.

References

Girolomoni G, Gisondi P . Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol Venereol. 2009; 23 Suppl 1:3-8. DOI: 10.1111/j.1468-3083.2009.03361.x. View

Frieder J, Kivelevitch D, Menter A . Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018; 9(1):5-21. PMC: 5761942. DOI: 10.1177/2040622317738910. View

Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L . Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules". Clin Rheumatol. 2018; 37(7):1739-1741. DOI: 10.1007/s10067-018-4090-6. View

Girolomoni G, Griffiths C, Krueger J, Nestle F, Nicolas J, Prinz J . Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. J Dermatolog Treat. 2014; 26(2):103-12. DOI: 10.3109/09546634.2014.880396. View

Armstrong A, Feldman S, Korman N, Meng X, Guana A, Nyirady J . Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2016; 28(3):200-205. DOI: 10.1080/09546634.2016.1214667. View

Kavanaugh A, Coates L, van der Windt D, Corp N, Soriano E . GRAPPA Treatment Recommendations: Updates and Methods. J Rheumatol Suppl. 2020; 96:41-45. DOI: 10.3899/jrheum.200126. View

Deodhar A, Helliwell P, Boehncke W, Kollmeier A, Hsia E, Subramanian R . Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10230):1115-1125. DOI: 10.1016/S0140-6736(20)30265-8. View

Gladman D, Antoni C, Mease P, Clegg D, Nash P . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 Suppl 2:ii14-7. PMC: 1766874. DOI: 10.1136/ard.2004.032482. View

Ritchlin C, Rahman P, Kavanaugh A, McInnes I, Puig L, Li S . Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the.... Ann Rheum Dis. 2014; 73(6):990-9. PMC: 4033144. DOI: 10.1136/annrheumdis-2013-204655. View

10.

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

11.

Viswanathan H, Chau D, Milmont C, Yang W, Erondu N, Revicki D . Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2014; 26(3):235-9. DOI: 10.3109/09546634.2014.943687. View

12.

Gudu T, Gossec L . Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018; 14(5):405-417. DOI: 10.1080/1744666X.2018.1468252. View

13.

Raychaudhuri S, Wilken R, Sukhov A, Raychaudhuri S, Maverakis E . Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2016; 76:21-37. DOI: 10.1016/j.jaut.2016.10.009. View

14.

Griffiths C, Jo S, Naldi L, Romiti R, Guevara-Sangines E, Howe T . A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018; 179(1):173-181. DOI: 10.1111/bjd.16332. View

15.

Revicki D, Willian M, Menter A, Saurat J, Harnam N, Kaul M . Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008; 216(3):260-70. DOI: 10.1159/000113150. View

16.

Feldman S, Bushnell D, Klekotka P, Scanlon M, Martin M, Wade S . Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2015; 27(3):224-7. DOI: 10.3109/09546634.2015.1093589. View

17.

Mahmood F, Coates L, Helliwell P . Current concepts and unmet needs in psoriatic arthritis. Clin Rheumatol. 2017; 37(2):297-305. DOI: 10.1007/s10067-017-3908-y. View

18.

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

19.

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

20.

Syed Y . Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2017; 18(1):147-158. DOI: 10.1007/s40257-017-0254-4. View